ClinicaliQ Trial Snapshot
- Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma — Recruiting • Phase III • Oncology • NCT06158841.
- What is being tested: Intravenous etentamig monotherapy is being evaluated against standard available therapies in adults with relapsed or refractory multiple myeloma to assess its efficacy and safety profile as a treatment option.
- Patient eligibility overview: The trial enrolls adult patients with multiple myeloma that has either relapsed (returned after initial treatment) or is refractory (resistant to standard therapies), representing a population with limited treatment options and poor prognosis.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come back (relapsed) or may not get better (refractory) with treatment. This is a study to determine change in disease symptoms of etentamig compared to standard available therapies in adult participants with relapsed/refractory (R/R) MM. Etentamig is an investigational drug being developed for…
Eligibility Snapshot
- : * Eastern Cooperative Oncology Group (ECOG) performance of
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.